Study identifier:D9950C00001
ClinicalTrials.gov identifier:NCT04504669
EudraCT identifier:2019-004539-22
CTIS identifier:N/A
A Phase I First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination with Durvaluamb (MEDI4736) in Participants with Advanced Solid Tumours.
Clear Cell Renal Cell Cancer
Phase 1
No
AZD8701
All
60
Interventional
18 Years - 101 Years
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Monotherapy Participants will receive AZD8701 intravenously, on Day 1, 3, 5 and 8 and then weekly for a maximum of 2 years. | Drug: AZD8701 FOXP3 antisense oligonucleotide |
Experimental: Combination Therapy Participants will receive AZD8701 (intravenously, on Day 1, 3, 5 and 8 and then weekly) and durvalumab (MEDI4736) intravenously monthly for a maximum of 2 years. | Drug: AZD8701 FOXP3 antisense oligonucleotide Biological/Vaccine: Durvalumab anti PDL-1 monoclonal antibody Other Name: MEDI4736 |